首页> 中文期刊> 《中国肿瘤临床 》 >初诊伴有脊柱转移的前列腺癌生存相关因素分析

初诊伴有脊柱转移的前列腺癌生存相关因素分析

             

摘要

Objective:Prostate cancer frequently metastasizes to the spine. In this study, we investigate the prognostic factors as-sociated with survival in patients with prostate cancer accompanied by spinal metastases at their preliminary diagnosis. Methods:Clin-ical data of 49 patients who were diagnosed with spinal metastasis from prostate cancer between January 2005 and December 2010 were analyzed. Variables including alkaline phosphatase (ALP), previous skeletal-related event, Gleason score, prostate-specific anti-gen (PSA) nadir, and time to castration resistance were obtained. Moreover, the relationship between these variables and overall sur-vival (OS) was analyzed. Survival analysis was performed by using Kaplan-Meier curves. Furthermore, the differences among the OS rates were assessed by using the log rank test. The variables were statistically significant in the univariate analysis (P<0.05) and were included in the multivariate model. Results:The average follow-up time was 64.1 months among the 49 patients. By the end of the follow-up, 41 of these patients were dead;the mean survival was 27 months. The 1-, 3-, and 5-year survival rate was 81.6%, 40.8%, and 20.4%, respectively. Univariate analysis identified that 6 variables were statistically significant prognostic factors of OS:with or without chemotherapy, ALP, previous skeletal-related event, Gleason score, PSA nadir, and time to castration resistance. The multivari-ate analysis showed that the time to castration resistance of ≥19 months and the addition of chemotherapy after disease progression are independent prognostic factors for a high OS. Conclusion:With or without chemotherapy and the time to castration resistance are the independent prognostic factors associated with survival in patients with prostate cancer accompanied by spinal metastases at first diagnosis.%目的:探讨初诊时伴有脊柱转移的前列腺癌患者与生存相关的因素。方法:收集2005年1月至2010年12月天津医科大学肿瘤医院接受内分泌治疗的前列腺癌脊柱转移患者49例,针对患者的碱性磷酸酶(ALP)、治疗前有无骨相关事件(SREs)、Gleason评分、治疗后PSA最低值、激素敏感持续时间、有无化疗行单因素分析,并对存在统计学意义者进行多因素分析。结果:平均随访时间64.1个月,死亡41例,中位生存时间为27个月,1、3、5年生存率分别是81.6%、40.8%、20.4%。单因素分析结果显示,有无联合化疗、ALP水平、治疗前是否出现SRE、Gleason评分、治疗后PSA最低值及激素敏感持续时间与总生存率(OS)有关(P<0.05)。Cox回归模型多因素分析显示,激素敏感持续时间≥19个月及联合化疗是较长生存时间的独立预后因素(P<0.05)。结论:激素敏感持续时间及进展为去势抵抗性前列腺癌(castration resistant prostate cancer,CRPC)后是否联合化疗是前列腺癌脊柱转移患者的预后独立因素。

著录项

  • 来源
    《中国肿瘤临床 》 |2015年第17期|862-865|共4页
  • 作者单位

    天津医科大学肿瘤医院骨与软组织肿瘤科;

    国家肿瘤临床医学研究中心;

    天津市肿瘤防治重点实验室 天津市300060;

    天津医科大学肿瘤医院骨与软组织肿瘤科;

    国家肿瘤临床医学研究中心;

    天津市肿瘤防治重点实验室 天津市300060;

    天津医科大学肿瘤医院骨与软组织肿瘤科;

    国家肿瘤临床医学研究中心;

    天津市肿瘤防治重点实验室 天津市300060;

    天津医科大学肿瘤医院骨与软组织肿瘤科;

    国家肿瘤临床医学研究中心;

    天津市肿瘤防治重点实验室 天津市300060;

    天津医科大学肿瘤医院骨与软组织肿瘤科;

    国家肿瘤临床医学研究中心;

    天津市肿瘤防治重点实验室 天津市300060;

    天津医科大学肿瘤医院骨与软组织肿瘤科;

    国家肿瘤临床医学研究中心;

    天津市肿瘤防治重点实验室 天津市300060;

  • 原文格式 PDF
  • 正文语种 chi
  • 中图分类
  • 关键词

    前列腺癌 ; 脊柱转移; 化疗; 内分泌治疗 ; 预后因素 ;

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号